No Data
No Data
No Data
No Data
No Data
Collegium Announces Authorized Generic Agreement With Hikma Pharmaceuticals USA Inc. for Nucynta and Nucynta ER
STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people
GlobeNewswireApr 29 20:00
Investors Don't See Light At End Of Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Tunnel
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) price-to-sales (or "P/S") ratio of 2.1x might make it look like a buy right now compared to the Pharmaceuticals industry in the United States, where arou
Simply Wall StApr 28 21:27
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious
GlobeNewswireApr 25 20:00
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
cls.cnApr 15 14:37
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the "Company"), a leading, diversified specialty pharmaceutical company committed to improving the
GlobeNewswireApr 11 20:00
Needham: Reiterates Collegium Pharmaceutical's (COLL.US) rating and adjusted from buy to buy rating, target price is $40.00.
Needham: Reiterates Collegium Pharmaceutical's (COLL.US) rating and adjusted from buy to buy rating, target price is $40.00.
Zhitong FinanceApr 11 18:01
No Data
No Data